Tackling the Tuberculosis Epidemic in sub-Saharan Africa - unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 46-49

  Zumla, Alimuddin ^a   Petersen, Eskild ^b   Nyirenda, Thomas ^c   Chakaya, Jeremiah ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c European Developing Countries Clinical Trials Partnership   (South Africa)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Capacity Development; Control; EDCTP; Epidemiology; HIV; Research; Sub Saharan Africa; Tuberculosis (TB)

Indexed keywords

AFRICA SOUTH OF THE SAHARA; ARTICLE; CLINICAL PRACTICE; COMMUNICABLE DISEASE; COMORBIDITY; DRUG RESISTANT TUBERCULOSIS; EPIDEMIC; EUROPEAN DEVELOPING COUNTRY CLINICAL TRIAL PARTNERSHIP PROGRAM; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SERVICE; HOUSING; HUMAN; LEADERSHIP; MEDICAL RESEARCH; MULTIDRUG RESISTANT TUBERCULOSIS; NON COMMUNICABLE DISEASE; PATIENT CARE; SOCIOECONOMICS; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; CLINICAL TRIAL (TOPIC); DEVELOPING COUNTRY; EUROPE; INTERNATIONAL COOPERATION; RESEARCH;

AFRICA SOUTH OF THE SAHARA; CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; EUROPE; HUMANS; INTERNATIONAL COOPERATION; RESEARCH; TUBERCULOSIS;

EID: 84925252707     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.12.039     Document Type: Article

References (41)

1. Murray C.J., Ortblad K.F., Guinovart C., Lim S.S., Wolock T.M., Roberts D.A., et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Sep 13, 384(9947):1005-1070.
2. World Health Organisation Global Tuberculosis report 2014. -accessed November 29th, 2014. WHO/HTM/TB/2014. http://www.who.int/tb/publications/global_report/en/.
3. Bates M., O'Grady J., Maeurer M., Tembo J., Chilukutu L., Chabala C., et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infectious Diseases. 2013, 13(1):36-42.
4. Bates M., O'Grady J., Mwaba P., Chilukutu L., Mzyece J., Cheelo B., et al. Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients. PLoS One. 2012, 7(7):e40774. doi: 10.137.
5. Bates M., Ahmed Y., Chilukutu L., Tembo J., Cheelo B., Sinyangwe S., et al. Use of the Xpert((R)) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia. Trop Med Int Health. 2013, 18(9):1134-1140.
6. Mudenda V., Lucas S., Shibemba A., O'Grady J., Bates M., Kapata N., et al. Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. J Infect Dis. 2012 May 15, 205(Suppl 2):S340-S346.
7. Abubakar I., Zignol M., Falzon D., Raviglione M., Ditiu L., et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013 Jun, 13(6):529-539.
8. Zumla A., Abubakar I., Raviglione M., Hoelscher M., Ditiu L., McHugh T.D., et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. 2012 May 15, 205(Suppl 2):S228-S240.
9. Wells W.A., Boehme C.C., Cobelens F.G., Daniels C., Dowdy D., Gardiner E., et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013, 13(5):449-458.
10. Report: The Global plan to stop TB 2011-2015. -accessed December 12th 2014. http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf.
11. WHO Report: Global strategy and targets for tuberculosis prevention, care and control after 2015. 29 November 2013 -accessed December 12th 2014. http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_12-en.pdf?ua=1.
12. Zumla A., Cobelens F. Operational research and MDG tuberculosis control targets. Lancet Infect Dis 2012, 12(4):262-263.
13. Raviglione M., Zumla A., Marais B., Horton R., Motsoaledi A. A sustainable agenda for tuberculosis control and research. Lancet 2012, 379(9821):1077-1078.
14. Herbert N., George A. Baroness Masham of I, Sharma V, Oliver M, Oxley A, Raviglione M, Zumla AI. World TB Day 2014: finding the missing 3 million. Lancet 2014, 383(9922):1016-1018.
15. Grange J.M., Zumla A. The global emergency of tuberculosis: what is the cause?. J R Soc Promot Health. 2002 Jun, 122(2):78-81.
16. Lawn S.D., Mwaba P., Bates M., Piatek A., Alexander H., Marais B.J. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013, 13(4):349-361.
17. Zumla A.I., Gillespie S.H., Hoelscher M., Philips P.P., Cole S.T., et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014 Apr, 14(4):327-340.
18. Phillips P.P., Gillespie S.H., Boeree M., Heinrich N., Aarnoutse R., McHugh T., et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis. 2012 May 15, 205(Suppl 2):S250-S257. Epub 2012 Mar 22. 10.1093/infdis/jis041.
19. Kaufmann S.H., Lange C., Rao M., Balaji K.N., Lotze M., Schito M., et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. The Lancet Respiratory Medicine. 2014, 2(4):301-320.
20. Sester M., Sotgiu G., Lange C., Giehl C., Girardi E., Migliori G.B. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011 Jan, 37(1):100-111.
21. Theron G., Zijenah L., Chanda D., Clowes P., Rachow A., Lesosky M., et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014 Feb 1, 383(9915):424-435. TB-NEAT team.
22. Costello A., Zumla A. Moving to research partnerships in developing countries. BMJ. 2000 Sep 30, 321(7264):827-829.
23. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ 1948, 2:769-782. Medical Research Council.
24. Zumla A., Huggett J., Dheda K., Green C., Kapata N., Mwaba P. Trials and tribulations of an African-led research and capacity development programme: the case for EDCTP investments. Trop Med Int Health 2010, 15:489-494.
25. ftp://ftp.cordis.europa.eu/pub/fp7/art169/docs/edctp.pdf Decision no 1209/2003/ec of the European parliament and of the council of 16 June 2003-accessed December 6, 2014. Official Journal of the European Union L169/1.
26. Olliaro P., Smith P.G. The European and Developing countries clinical trials partnership. J HIV Ther 2004, 9:53-56.
27. Mgone C., Volmink J., Coles D., Makanga M., Jaffar S., Sewankambo N. Linking research and development to strengthen health systems in Africa. Trop Med Int Health 2010, 15:1404-1406.
28. Matee M.I., Manyando C., Ndumbe P.M., Corrah T., Jaoko W.G., Kitua A.Y., et al. European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership. BMC Public Health 2009, 9:249.
29. Mgone C.S., Salami W. EDCTP: a genuine north-south partnership. Trop Med Int Health 2009, 14:1327-1328.
30. Mgone C.S., Makanga M. Fighting HIV/AIDS, tuberculosis and malaria: one world, one partnership. Trop Med Int Health 2010, 15:973-974.
31. Editorial: Europe's science bureaucrats should learn from Gates success. Lancet 2005, 366:2-3.
32. Editorial. Europe's clinical trials partnership in peril. Lancet 2007:4 Aug. 374:362.
33. EDCTP Annual Report 2013: -Accessed October 16th, 2014. http://www.edctp.org/annualreport2013/EDCTP_Annual_Report_2013_EN.pdf.
34. PANACEA -accessed December 12th 2014. http://panacea-tb.net/.
35. Gillespie S., Crook A.M., McHugh T.D., Mendel C.M., Meredith S.K., Murray S., et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014, 371:1577-1587.
36. Jindani A., Harrison T.S., Nunn A.J., Phillips P.P., Churchyard G.J., Charalambous S., et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014, 371:1599-1608.
37. Zumla A., Makanga M., Nyirenda T., Beattie P., Olesen O.F., Breugelmans J.G., et al. Genesis of EDCTP2. Lancet Infect Dis. 2014 Dec 1, pii: S1473-3099(14)71034-5.
38. Decision No 556/2014/EU of the European Parliament and of Council of 15 May 2014 on the participation of the Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken by several Member States. Official Journal of the European Union L169/38. -accessed 16th October, 2014. http://www.edctp.org/fileadmin/documents/Towards_EDCTP_II/EDCTP2-Decision556_2014_EU_2014-05-15.pdf.
39. Al-Tawfiq J.A., Zumla A., Gautret P., Gray G.C., Hui D.S., Al-Rabeeah A.A., et al. Surveillance for emerging respiratory viruses. Lancet Infect Dis. 2014 Oct, 14(10):992-1000.
40. Mandala W.L., Cowan F.M., Lalloo D.G., Wilkinson R.J., Kelly P., Chidzonga M.M., et al. Southern Africa Consortium for Research Excellence (SACORE): successes and challenges. Lancet Glob Health. 2014 Dec, 2(12):e691-e692. 10.1016/S2214-109X(14)70321-3.
41. 2014 Report on Tuberculosis Research Funding Trends" Treatment Action Group, accessed 12/11/2014. http://www.treatmentactiongroup.org/tbrd2014.